Esophageal Cancer - Pipeline Review, H2 2018

Global Markets Direct
779 Pages - GMD17621
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
Table of Contents 2
Introduction 6
Esophageal Cancer - Overview 7
Esophageal Cancer - Therapeutics Development 8
Esophageal Cancer - Therapeutics Assessment 26
Esophageal Cancer - Companies Involved in Therapeutics Development 40
Esophageal Cancer - Drug Profiles 77
Esophageal Cancer - Dormant Projects 747
Esophageal Cancer - Discontinued Products 752
Esophageal Cancer - Product Development Milestones 753
Appendix 764

List of Tables
Number of Products under Development for Esophageal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Esophageal Cancer - Pipeline by AbbVie Inc, H2 2018
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Esophageal Cancer - Pipeline by Ambrx Inc, H2 2018
Esophageal Cancer - Pipeline by amcure GmbH, H2 2018
Esophageal Cancer - Pipeline by AMI Onco Theranostics LLC, H2 2018
Esophageal Cancer - Pipeline by Apexigen Inc, H2 2018
Esophageal Cancer - Pipeline by Aprea AB, H2 2018
Esophageal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
Esophageal Cancer - Pipeline by Bayer AG, H2 2018
Esophageal Cancer - Pipeline by BeiGene Ltd, H2 2018
Esophageal Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2018
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
Esophageal Cancer - Pipeline by Cantargia AB, H2 2018
Esophageal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2018
Esophageal Cancer - Pipeline by Celgene Corp, H2 2018
Esophageal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2018
Esophageal Cancer - Pipeline by Cristal Therapeutics BV, H2 2018
Esophageal Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2018
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Esophageal Cancer - Pipeline by CytomX Therapeutics Inc, H2 2018
Esophageal Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Eli Lilly and Co, H2 2018
Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Esophageal Cancer - Pipeline by FLX Bio Inc, H2 2018
Esophageal Cancer - Pipeline by Genmab A/S, H2 2018
Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2018
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2018
Esophageal Cancer - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2018
Esophageal Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2018
Esophageal Cancer - Pipeline by Immunocore Ltd, H2 2018
Esophageal Cancer - Pipeline by Immunomedics Inc, H2 2018
Esophageal Cancer - Pipeline by Incyte Corp, H2 2018
Esophageal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2018

List of Figures
Number of Products under Development for Esophageal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838